|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the ISTA 10-K filed Feb 23, 2009. Other Product Candidates and Development Activities In addition to the products presently in human clinical trials, we have a number of products that may be ready for late stage clinical study initiation within the next twelve to eighteen months. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma. In 2006, we acquired exclusive North American rights to both iganidipine and novel prostaglandin formulations under licensing agreements with Senju. We continually evaluate opportunities for late-stage or currently-marketed complementary products and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. Other Product Candidates and Development Activities In addition to the products presently in human clinical trials, we have a number of products that may be ready for late stage clinical study initiation within the next twelve to eighteen months. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma. In 2006, we acquired exclusive North American rights to both iganidipine and novel prostaglandin formulations under licensing agreements with Senju. We continually evaluate opportunities for late-stage or currently-marketed complementary products and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. Other Product Candidates and Development Activities In addition to the products presently in human clinical trials, we have a number of products that may be ready for late stage clinical study initiation within the next twelve to eighteen months. These include a strong steroid product candidate to treat ocular inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma. In 2006, we acquired exclusive North American rights to both iganidipine and novel prostaglandin formulations under licensing agreements with Senju. We continually evaluate opportunities for late-stage or currently-marketed complementary products and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. These excerpts taken from the ISTA 10-K filed Mar 7, 2008. Other Product Candidates and Development Activities In addition to the products presently in human clinical trials, we have a number of products that may be ready for late stage clinical study initiation within the next twelve to eighteen months. These include a Xibrom/steroid combination product to treat inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma. In 2006, we acquired exclusive North American rights to both iganidipine and a new formulation of latanoprost under licensing agreements with Senju. We continually evaluate opportunities for late-stage or currently marketed complementary products and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. Other Product Candidates and Development In addition to the products presently in human clinical trials, we have a number of products that may be ready for late and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. This excerpt taken from the ISTA 10-K filed Mar 16, 2007. Other Product Candidates and Development Activities In addition to the products presently in human clinical trials, we have a number of products that will be ready for late stage clinical study initiation within the next twelve to eighteen months. These include a Xibrom/steroid combination product to treat inflammation, iganidipine to enhance ocular nerve blood flow and a new formulation of latanoprost for the treatment of glaucoma. In 2006, we acquired exclusive North American rights to both iganidipine and a new formulation of latanoprost under licensing agreements with Senju. We continually evaluate opportunities for late-stage or currently marketed complementary product and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. This excerpt taken from the ISTA 10-K filed Mar 6, 2006. Other Product Candidates and Development Activities We continually evaluate opportunities for late-stage or currently marketed complementary product and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. Our ability to execute on such opportunities in some circumstances may be dependent upon our ability to raise additional capital on commercially reasonable terms. This excerpt taken from the ISTA 10-Q filed Nov 9, 2005. Other Product Candidates and Development Activities
We continually evaluate opportunities for late-stage or currently marketed complementary product and for expansion of our existing product franchises and, if and when appropriate, intend to pursue such opportunities through further product acquisitions and related development activities. For example, we have initiated work on a strong steroid eye drop being developed to treat ocular inflammation. Our ability to execute on such opportunities in some circumstances will be dependent upon our ability to raise additional capital on commercially reasonable terms.
| EXCERPTS ON THIS PAGE:
|
| |||||||
